| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
| [2] |
Yimlamai D, Fowl BH, Camargo FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer[J]. J Hepatol, 2015, 63(6):1491-1501.
|
| [3] |
Feng G, Li J, Zheng M, et al. Hepatitis B virus X protein up-regulates C4b-binding protein α through activating transcription factor Sp1 in protection of hepatoma cells from complement attack[J]. Oncotarget, 2016, 7(19):28013-28026.
|
| [4] |
Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer[J]. Cell, 2015, 163(4):811-828.
|
| [5] |
Hong L, Cai Y, Jiang M, et al. The Hippo signaling pathway in liver regeneration and tumorigenesis[J]. Acta Biochim Biophys Sin, 2015, 47(1):46-52.
|
| [6] |
Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers[J]. Cancer Biol Ther, 2013, 14(5):390-398.
|
| [7] |
Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment[J]. Nat Rev Drug Discov, 2014, 13(1):63-79.
|
| [8] |
Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells[J]. Cell, 2011, 147(4):759-772.
|
| [9] |
Juan WC, Hong W. Targeting the Hippo signaling pathway for tissue regeneration and cancer therapy[J]. Genes, 2016, 7(9):E55.
|
| [10] |
Wu H, Xiao Y, Zhang S, et al. The Ets transcription factor GABP isa component of the hippo pathway essential for growth and antioxidant defense[J]. Cell Rep, 2013, 3(5):1663-1677.
|
| [11] |
Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development[J].J Hepatol, 2014, 61(5):1088-1096.
|
| [12] |
Li H, Wang S, Wang G, et al. Yes-associated protein expression isa predictive marker for recurrence of hepatocellular carcinoma after liver transplantation[J]. Dig Surg, 2014, 31(6):468-478.
|
| [13] |
Zhang XD, Wang Y, Ye LH. Hepatitis B virus X protein accelerates the development of hepatoma[J]. Cancer Biol Med, 2014, 11(3):182-190.
|
| [14] |
Xu C, Zhou W, Wang Y, et al. Hepatitis B virus-induced hepatocellular carcinoma[J]. Cancer Lett, 2014, 345(2):216-222.
|
| [15] |
Toh ST, Jin Y, Liu L, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations[J]. Carcinogenesis, 2013, 34(4):787-798.
|
| [16] |
Jung SY, Kim YJ. C-terminal region of HBx is crucial for mitochondrial DNA damage[J]. Cancer Lett, 2013, 331(1):76-83.
|
| [17] |
Sze KM, Chu GK, Lee JM, et al. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma[J]. Hepatology, 2013, 57(1):131-139.
|
| [18] |
Yip WK, Cheng AS, Zhu R, et al. Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development[J]. PLoS One, 2011, 6(8):e22888.
|
| [19] |
Esteller M. Non-coding RNAs in human disease[J]. Nat Rev Genet, 2011, 12(12):861-874.
|
| [20] |
Huang JF, Guo YJ, Zhao CX, et al. Hepatitis B Virus X Protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin[J]. Hepatology, 2013, 57(5):1882-1892.
|
| [21] |
Li CH, Xu F, Chow S, et al. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression[J]. Eur J Cancer, 2014, 50(15):2560-2569.
|
| [22] |
Lu ZP, Xiao ZL, Yang Z, et al. Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1[J]. Acta Pharmacol Sin, 2015, 36(10):1228-1236.
|
| [23] |
Bak Y, Shin HJ, Bak Is, et al. Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein1 pathway[J]. Biochem Biophys Res Commun, 2015, 466(4):676-681.
|
| [24] |
Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis[J]. J Gastroenterol, 2011, 46(8):974-990.
|
| [25] |
Wu Y, Zhang J, Zhang H, et al. Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma[J]. Oncol Lett, 2016, 12(3):1971-1974.
|
| [26] |
Liu P, Zhang H, Liang X, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma[J]. Oncotarget, 2015, 6(30):29048-29059.
|
| [27] |
Zhang T, Zhang J, You X, et al. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells[J]. Hepatology, 2012, 56(6):2051-2059.
|
| [28] |
Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP[J]. Genes Dev, 2012, 26(12):1300-1305.
|
| [29] |
Jiao S, Wang H, Shi Z, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer[J]. Cancer Cell, 2014, 25(2):166-180.
|